Evidence map›Paper›PMID 36851931›Full record

ArticleSouth Asian journal of cancer2023

Challenges in Cervical Cancer Prevention: Real-World Scenario in India.

Satinder Kaur, Lalit Mohan Sharma, Vinita Mishra, Maj Gen Bhupesh Goyal, Swasti Swasti, Avinash Talele, Purvish M Parikh

Open access · diamondAbstract read
In one paragraph

Article in South Asian journal of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
6.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Satinder KaurDepartment of Gynae Oncology, Dharamshila Narayana Super Speciality Hospital, Delhi, India.
Lalit Mohan SharmaDepartment of Medical Oncology and Clinical Hematology, Mahatma Gandhi Medical College Hospital, Jaipur, Rajasthan, India.
Vinita MishraDepartment of Gynaecology, Ishi Clinic, Prayagraj, Uttar Pradesh, India.
Maj Gen Bhupesh GoyalDepartment of Gynaecology, Command Hospital, Pune, Maharashtra, India.
Swasti SwastiDepartment of Gynaecological Oncology, Max Hospital, New Delhi, India.
Avinash TaleleDepartment of Medical Oncology, Apollo Hospital, Navi Mumbai, Maharashtra, India.
Purvish M ParikhDepartment of Clinical Hematology, Mahatma Gandhi University of Health Sciences and Technology, Jaipur, Rajasthan, India.
Apollo Hospitals · INCommand Hospital · INGandhi Medical College & Hospital · INMahatma Gandhi University · INMax Healthcare · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Satinder KaurIn spite of global falling trends, cervical cancer remains a major healthcare challenge for India, South Asia Association for Regional Cooperation region, and other low- and middle-income countries. Our survey was to document the real-world challenges that still exist in India. A total of 316 eligible and complete responses to the 21 questions were analyzed. Screening of mothers and vaccinating their daughters was considered as the most important strategy to prevent cervical cancer by 65.8% (208/316). Screening was offered to all asymptomatic eligible females by 79% (250/316). Improvement in screening rates requires promoting the national program (67.7%; 214/316), strengthening existing infrastructure (62%; 196/316), regular training of primary healthcare workers (57.6%; 182/316), and increasing awareness among schools and colleges (57.9%; 183/316). Almost all responders (93%; 294/316) wanted to have human papillomavirus (HPV) vaccination included in the national immunization schedule. Cost of vaccine was considered a major roadblock. If it became available at INR 250 per dose, 96.8% (306/316) respondents would recommend it for all eligible patients. With the impending availability of this indigenous tetravalent HPV vaccine jointly produced by Department of Biotechnology, Govt of India and Serum Institute of India, the war against cervical cancer just got easier.

Indexed as

HPVpublic healthvaccinationVIAVILI

Identifiers

PMID36851931
PMCPMC9966165
OpenAlexW4322097620

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.